Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.

Hae Jin KimYoung Sik KimChang Beom LeeMoon-Gi ChoiHyuk-Jae ChangSoo Kyoung KimJae Myung YuTae Ho KimJi Hyun LeeKyu Jeung AhnKyung Wan MinEun Jung KyungYeo Kyeong KimKwan-Woo Lee

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

Our results suggest the significant glucose-lowering effect of teneligliptin after switching from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic control was maintained for up to 52 weeks without safety concerns.

Keyphrases

glycemic control
blood glucose
type diabetes
weight loss
randomized controlled trial
metabolic syndrome
blood pressure
clinical trial
gestational age
adipose tissue
double blind